sCLU regulates cisplatin chemosensitivity of lung cancer cells in vivo

Guoliang Ma¹, Hengjuan Cai², Lizhen Gao³, Mei Wang³ and Haixia Wang⁴*

Abstract

Background: In a previous analysis using a lung cancer cell line model, we have found that therapies directed against secreted clusterin (sCLU) and its downstream signaling targets pAkt and pERK1/2 may have the potential to enhance the efficacy of cisplatin (DDP)-based chemotherapy in vitro. Here, we investigated the therapies directed against sCLU on the DDP-based chemotherapy in vivo and explored the mechanism.

Methods: Using lung cancer cell lines, A549 cells and DDP-resistant A549 cells (A549DDP), we determined the effect of sCLU silencing using short interfering double-stranded RNA (siRNA) on chemosensitivity in immunocompromised mice bearing A549DDP tumors. We then determined the effect of sCLU overexpression via stable sCLU transfection on chemosensitivity in immunocompromised mice bearing A549 tumors. The effect of sCLU silencing or overexpression on pAkt and pERK1/2 expression and chemosensitivity in vivo was detected by Western blot assay.

Results: The results showed sCLU silencing increased the chemosensitivity of A549DDP cells to DDP in vivo via downregulation of pAkt and pERK1/2 expression. And sCLU overexpression decreased the chemosensitivity of A549 cells to DDP in vivo via upregulation of pAkt and pERK1/2 expression.

Conclusions: We therefore concluded that the DDP-induced sCLU activation, which involved induction of pAkt and pERK1/2 activation that confer DDP resistance in immunocompromised mice and alteration of this balance, allows sensitization to the antitumor activity of cisplatin chemotherapy.

Keywords: Lung cancer, Chemotherapy, Clusterin, AKT, ERK1/2

Background

Lung cancer is known to be the most frequent cancer worldwide and the incidence of this epidemic disease is continuing to increase at 0.5% per year globally [1]. Because of the size and distribution of lung cancer, the cytoreductive surgery is not very effective for this disease and therefore chemotherapy and/or radiation are the only treatments of choice. Despite major advances in patient management, chemotherapy and radiotherapy, nearly 80% of the patients still die within 1 year of diagnosis and long-term survival is obtained only in 5% to 10% of cases [1].

Cisplatin (DDP) has been the most widely used drug in first-line chemotherapy. The major obstacle in lung cancer chemotherapy is the emergence of inherent and acquired drug resistance in cancer cells [2,3]. The efficacy of chemotherapy is thus limited. To overcome this resistance, often higher doses of toxic anticancer drugs are administered to cancer patients, thus resulting in adverse side effects to healthy organs and tissues. In this regard, reversal of drug resistance is one of the most attractive ways to significantly enhance therapeutic efficacy in lung cancers.

The cytoprotective chaperone protein, clusterin, is synthesized as full-length clusterin (60 kDa) in the mitochondria and is targeted to the endoplasmic reticulum, where it is glycosylated, proteolytically cleaved into an a and b chain, and secreted into the extracellular matrix as the secreted form of clusterin (40 kDa). Clusterin protein is commonly upregulated by cytotoxic chemotherapy and radiotherapy in cancer cells and contributes to cancer cell resistance in vitro and in various animal models of cancer by blocking apoptosis [4]. Recent clinical trials of OGX-011, an antisense oligonucleotide specifically

* Correspondence: whxblood@126.com

¹Department of Blood Transfusion, The Affiliated Hospital of Weifang Medical College, Weifang, China

© 2015 Ma et al., licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
targeting clusterin, have shown promise when combined with chemotherapy in cancer patients [5]. Several in vitro studies have examined the role of clusterin in carcinogenesis, lung cancer progression, and response to chemo- and radiotherapy [6-14]. Studies performed in lung cancer cell lines and animal models showed that clusterin is upregulated after exposure to chemo- and radiotherapy [7,8,11]. A potential role proposed for the protein is cytoprotective. In vitro, clusterin silencing by antisense oligonucleotides (ASO) and small-interfering RNAs (siRNA) directed against clusterin mRNA in clusterin-rich lung cancer cell lines sensitized cells to chemotherapy and radiotherapy and decreased their metastatic potential [8,9,11,12,14].

We have shown secreted clusterin (sCLU) silencing directed against sCLU mRNA in sCLU-rich lung cancer cell lines sensitized cells to DDP chemotherapy in vitro [11]. The molecular mechanisms underlying the effect of sCLU silencing on lung cancer cell chemosensitivity is via its downstream signaling targets pAKT and pERK1/2. The current study investigated the significance of clusterin (sCLU) silencing on DDP chemosensitivity in lung cancer cell lines in vivo and investigated the molecular mechanisms underlying the effect of sCLU silencing.

**Methods**

**Cell lines**

Human lung adenocarcinoma bronchioloalveolar carcinoma A549 cells and cisplatin (DDP) resistant A549 cells (A549DDP) were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured at 37°C in a humidified atmosphere containing 5% CO2 in Ham's F12 medium supplemented with sodium bicarbonate (2.2%, w/v), L-glutamine (0.03%, w/v), penicillin (100 units/ml), streptomycin (100 μg ml⁻¹), and fetal calf serum (10%).

**Reagents**

Akt (Ab-473) antibody (E021054-2), ERK1/2 (Ab-202/204) antibody (E022017-2), ERK1/2 (Phospho-Thr202/Tyr204) antibody (E012017-2), AKT (Phospho-Ser473) antibody (E011054-2) and β-actin antibody (5B7) (E12-041-3), clusterin (A-9) (sc-166907, 1:200), the enhanced chemiluminescence detection kit, and DDP were preserved in our laboratory [11]. The molecular mechanisms underlying the effect of sCLU silencing on lung cancer cell chemosensitivity is via its downstream signaling targets pAKT and pERK1/2. The current study investigated the significance of clusterin (sCLU) silencing on DDP chemosensitivity in lung cancer cell lines in vivo and investigated the molecular mechanisms underlying the effect of sCLU silencing.

**Western blotting**

Tumor tissues were excised, minced, and homogenized in protein lystate buffer. Debris was removed by centrifugation. Samples containing 40 μg of total protein were resolved on 12% polyacrylamide SDS gels and electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% skim milk and incubated with primary antibody and subsequently with an alkaline phosphatase-conjugated secondary antibody. Blots were stained with an anti-β-actin Ab to confirm that each lane contained similar amounts of homogenate.

**In situ detection of apoptotic cells**

Tumor sections were stained with the TUNEL agent (Roche, Shanghai, China), and the TUNEL-positive cells

(A549DDP/sCLU-shRNA and A549DDP/shRNA) as reported previously [11].

**Subcutaneous implantation of tumor cells**

A549, A549DDP, A549/sCLU, A549/pCDNA3.1, A549DDP/sCLU-shRNA, and A549DDP/shRNA cells were harvested from subconfluent cultures after a brief exposure to 0.25% trypsin and 0.2% EDTA. Trypsinization was stopped by adding medium containing 10% FBS. The cells were washed once in serum-free medium and resuspended in PBS. Only suspension consisting of a single cell with >90% viability was used for the injections. Cells (2 × 10⁶) in 100 μl PBS were injected s.c into the right flank on 6-week-old male nude (athymic) mice with a 27-gauge hypodermic needle, respectively. In our previous experience with this model, tumors take rate of >95% was obtained.

**Experimental protocol**

All surgical procedures and care administered to the animals were in accordance with institutional animal ethic guidelines. Tumors were established by subcutaneous injection of 2 × 10⁶/A549 tumor cells (A549, A549DDP, A549/sCLU, A549/pCDNA3.1, A549DDP/sCLU-shRNA, A549DDP/shRNA, respectively) into the flanks of mice. Tumor volumes were estimated according to the formula: p/6 × a² × b, where a is the short axis and b the long axis. When tumors reached ~100 mm³ at about 3 weeks, the mice were randomly assigned to 2 groups (each group had 8 mice): control and DDP. Mice received daily 200 μl i.p. injections of either PBS or DDP (4 mg/kg body/wt.,i.p), respectively. DDP was administered i.v. once every 3 days. The treatments lasted for 15 days during which the size of the tumors was recorded. The mice were euthanized 3 days after the last injection, and tumors were excised. Each tumor was divided into two halves, one half was fixed with 10% buffered formalin and the other stored at ~80°C.
were counted in 10 randomly selected × 400 high-power fields under microscopy. The apoptosis index was calculated according to the following formula: the number of apoptotic cells/total number of nucleated cells × 100%.

**Statistical analysis**

Data were expressed as mean ± standard deviation (SD). Experiments were performed at least in triplicate. Comparisons were done with two-tailed Student’s t test or ANOVA. A value of \( P < 0.05 \) was considered statistically significant.

**Results**

Clusterin overexpression *in vivo* significantly increased the resistance of the lung cancer cells to cisplatin

Based on the *in vitro* experiment of clusterin in the cisplatin resistance of lung cancers [11], we further examined if clusterin expression affects the cisplatin sensitivity *in vivo*. A549, A549/sCLU, and A549/pCDNA3.1 cells were injected subcutaneously into the right flank of nude mice. Cisplatin could significantly inhibit the tumor growth in mice injected with A549/pCDNA3.1 scramble cells and A549 cells compared to the mice injected with A549/sCLU cells (Figure 1A). As shown in Figure 1A, the A549 tumors of mice treated with DDP only reached \( 530 ± 18.6 \text{ mm}^3 \) in volume 36 days after treatment, which was significantly smaller compared to A549/sCLU cells (\( 1184.4 ± 102.6 \text{ mm}^3 \)) in volume 36 days after DDP treatment (\( P < 0.05 \)). Clusterin overexpression alone showed no significant growth inhibition compared to the control group.

Tumor sections prepared from the three groups were stained with the TUNEL agent to detect apoptotic cells. The results in Figure 2B showed that there were more apoptotic cells in tumors (A549 and A549/pCDNA3.1) treated with DDP compared with the control tumors. There were few apoptotic cells in tumors (A549/sCLU) treated with DDP, compared with the control tumors (Figure 1B, \( P < 0.05 \)). Clusterin overexpression alone showed no significantly increased apoptosis compared to the control group.

Clusterin silencing *in vivo* significantly decreased the resistance of the lung cancer cells to cisplatin

To compare the *in vivo* antitumor activities of clusterin silencing and DDP monotherapies, the two therapies were evaluated in an A549\(^{DDP}\) mouse xenograft model. We found no significant decreases in tumor volume with clusterin silencing and DDP monotherapies (Figure 2A, \( P > 0.05 \)). Furthermore, no significantly increased apoptotic cells in tumors were found (Figure 2B, \( P > 0.05 \)).

We further examined if clusterin silencing affects the cisplatin sensitivity *in vivo*. A549\(^{DDP}\)/sCLU shRNA cells were injected subcutaneously into the right flank of nude mice. As shown in Figure 2A, combined with DDP and sCLU shRNA; the tumor growth was significantly inhibited (Figure 2A, \( P < 0.05 \)). Furthermore, the apoptotic

**Figure 1** Clusterin overexpression decreased chemotherapeutic sensitivity and inhibited apoptosis of DDP sensitive A549 cells. (A) Cells transfected with pCDNA3.1/sCLU or scramble pCDNA3.1 were injected subcutaneously into the right flank of nude mice. When tumors reached \( \sim 100 \text{ mm}^3 \) in volume, the mice received daily 200 μl i.p. injections of DDP (4 mg/kg body/wt./l). DDP was administered i.v. once every 3 days. The treatments lasted for 15 days during which the volume of tumors was recorded; \( * P < 0.05 \) vs pCDNA3.1/sCLU + DDP (Student’s t test). (B) Tumor sections were stained with TUNEL agent to visualize apoptotic cells. \( * P < 0.05 \) (Student’s t test).
cells in tumors were significantly increased when treatment combined with DDP and sCLU shRNA were compared with control (Figure 2B, *P* < 0.05). These findings suggest that clusterin contributes to DDP resistance in lung cancer cells in xenograft tumor models.

**Clusterin silencing in vivo significantly decreased pERK1/2 and pAkt**

Western blot indicated that the expression of clusterin, pAkt, and pERK1/2 in A549 solid tumors was weak, while it was rich in the DDP-treated A549 solid tumors (Figure 3A). In the A549DDP solid tumor, the expression of clusterin, pAkt, and pERK1/2 in A549 solid tumors was very rich; however, in the DDP-treated A549DDP solid tumors, no apparent increase of clusterin, pAkt, and pERK1/2 expression was found (Figure 3B). In the A549DDP/sCLU shRNA solid tumor, the expression of clusterin, pAkt, and pERK1/2 in A549 solid tumors was very weak; furthermore, in the DDP-treated A549DDP/sCLU shRNA solid tumors, the clusterin, pAkt, and pERK1/2 expression was also very weak (Figure 3C).

These findings suggest that clusterin silencing inhibits DDP-induced increase of clusterin, pAkt, and pERK1/2 expression; clusterin silencing contributes to DDP sensitivity in lung cancer cells in xenograft tumor models, and pERK1/2 and pAkt downregulation was involved in the procedure.

**Clusterin overexpression in vivo significantly increased pERK1/2 and pAkt expression**

It has demonstrated above that the expression of clusterin, pAkt, and pERK1/2 in A549 solid tumors was weak (Figure 3A); however, clusterin, pAkt, and pERK1/2 expression was very rich after DDP treatment of solid tumors (Figure 4). In the DDP-treated A549/sCLU solid tumors, clusterin, pAkt, and pERK1/2 expression was not markedly increased than that in the control group.
that the chemotherapeutic agent DDP activated sCLU, which increased cellular DDP chemoresistance in the A549DDP and sCLU transfected A549 cells via inhibition DDP-induced apoptosis; whereas sCLU knockdown induced chemosensitization in the A549 and A549DDP cells via increase of DDP-induced apoptosis. Further study indicated therapies directed against sCLU have the potential to enhance the efficacy of DDP-based chemotherapy via downregulation of pAKT and pERK1/2.

The current study investigated the significance of clusterin (CLU), in its cytoplasmic secretory form (sCLU), has the unique property in mediating chemoresistance to numerous unrelated anticancer agents and its presence has been observed in a variety of solid tumors and lymphoma [19]. Previous reports from our laboratory [11] have demonstrated in vitro that the chemotherapeutic agent DDP activated sCLU, which increased cellular DDP chemoresistance in the A549DDP and sCLU transfected A549 cells via inhibition DDP-induced apoptosis; whereas sCLU knockdown induced chemosensitization in the A549 and A549DDP cells via increase of DDP-induced apoptosis. Further study indicated therapies directed against sCLU have the potential to enhance the efficacy of DDP-based chemotherapy via downregulation of pAKT and pERK1/2.

Figure 4 Expression of clusterin, pERK1/2 and pAKT in A549 tumor tissue from the mice. A549, A549/sCLU, and A549/sCLU solid tumors (Figure 4). These findings suggest that clusterin overexpression contributes to DDP resistance in lung cancer cells in xenograft tumor models, and pERK1/2 and pAKT overexpression was involved in the procedure.

Discussion

Despite significant advances in oncology over the last several decades, lung cancer remains highly lethal. Most patients present with advanced disease and are often inoperable at the time of diagnosis. Adjuvant cisplatin-based chemotherapy is the standard of care for completely resected high-risk stage IB and stage II NSCLC based on an approximately 5% improvement in 5-year overall survival [15]. Five promising new drugs have been shown to achieve survival rates equivalent or superior to cisplatin, and when used in combination with cisplatin or carboplatin, RRs are as high as 40% to 50%. These agents include paclitaxel, docetaxel, vinorelbine, irinotecan, and gemcitabine [16]. The limited efficacy of cytotoxic chemotherapy and radiotherapy remains a major obstacle for the treatment of patients with advanced lung cancer.

Resistance to anticancer agents is one of the primary impediments to effective cancer therapy. Chemoresistance occurs not only to clinically established therapeutic agents but also to novel targeted therapeutics. Both intrinsic and acquired mechanisms have been implicated in drug resistance, but it remains controversial which mechanisms are responsible that lead to failure of therapy in cancer patients [17]. Chemoresistance may also develop from alterations in the apoptotic machinery, secondary to increased activity of anti-apoptotic pathways or the expression of anti-apoptotic genes. Ironically, agents used to destroy malignant cells may also induce the expression of genes that mediate radiation- and chemoresistance. Survival proteins upregulated after apoptotic triggers that function to inhibit cell death include anti-apoptotic members of the bcl-2 protein family, clusterin, HSPs, and survivin [18].

Clusterin (CLU), in its cytoplasmic secretory form (sCLU), has the unique property in mediating chemoresistance to numerous unrelated anticancer agents and its presence has been observed in a variety of solid tumors and lymphoma [19]. Previous reports from our laboratory [11] have demonstrated in vitro that the chemotherapeutic agent DDP activated sCLU, which increased cellular DDP chemoresistance in the A549DDP and sCLU transfected A549 cells via inhibition DDP-induced apoptosis; whereas sCLU knockdown induced chemosensitization in the A549 and A549DDP cells via increase of DDP-induced apoptosis. Further study indicated therapies directed against sCLU have the potential to enhance the efficacy of DDP-based chemotherapy via downregulation of pAKT and pERK1/2.

The current study investigated the significance of clusterin (sCLU) silencing on DDP chemosensitivity in lung cancer cell lines and investigated the molecular mechanisms underlying the effect of sCLU silencing in vivo. In the first study, six groups of mice (n = 6) with A549DDP/shRNA sCLU tumors received doses of PBS (control) or cisplatin at the doses described. Tumor volumes were monitored during the study period at least twice a week. No significant decreases in tumor volume were observed with clusterin silencing and DDP monotherapies, alone. Furthermore, no significantly increased apoptotic cells in tumors were found. However, combined with DDP and sCLU shRNA, the tumor growth was significantly inhibited, and the apoptotic cells in tumors were significantly increased when treatment was combined with DDP and sCLU shRNA. Further study indicated clusterin was overexpressed in the A549DDP cells. Clusterin silencing contributes to DDP sensitiveness in vivo via pERK1/2 and pAKT downregulation. In the next study, six groups of mice (n = 6) with A549/sCLU tumors received doses of PBS (control) or cisplatin at the doses described. The results showed sCLU overexpression was resistant to DDP-induced apoptosis. This effect was via pERK1/2 and pAKT upregulation.

Conclusions

In summary, these data demonstrate that suppression of clusterin expression via siRNA transfection attenuates its anti-apoptotic effects and enhances chemosensitivity by downregulation of pERK1/2 and pAKT in vivo. These experimental data support the development of targeted strategies employing clusterin siRNA complementary to conventional cytotoxic therapies for advanced lung cancer.
Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
GM and HC carried out the plasmid transfection and drafted the manuscript. LG and HW carried out in situ detection of apoptotic cells. MW carried out western blot assay. MW and HW participated in the design of the study and performed the statistical analysis. All authors read and approved the final manuscript.

Author details
1Department of Clinical Lab, People’s Hospital of Laiwu, Laiwu, China.
2Department of neurology, People’s Hospital of Zhangqiu, Zhangqiu, China.
3Department of Clinical Lab, People’s Hospital of Zhangqiu, Zhangqiu, China.
4Department of Blood Transfusion, The Affiliated Hospital of Weifang Medical College, Weifang, China.

Received: 3 May 2014 Accepted: 9 February 2015
Published online: 25 February 2015

References
1. Fridman E, Skarda J, Pinthus JH, Ramon J, Mor Y. Expression of multidrug resistance-related protein (MRP-1), lung resistance-related protein (LRP) and topoisomerase-II (TOPO-II) in Wilms’ tumor: immunohistochemical study using TMA methodology. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152:47–51.
2. Scaglitti GV, Novello S, Selvaggi G. Multidrug resistance in non-small-cell lung cancer. Ann Oncol. 1999;10 Suppl 5:S85–6.
3. Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des. 2006;12:273–86.
4. Shannan B, Seifert M, Leskov K. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ. 2006;13:12–9.
5. Chi KN, Eisenhauer E, Fazli L. A phase I pharmacokinetic and pharmacodynamic study of oxg-011, a 20-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst. 2005;97:1287–96.
6. Miyake H, Gleave ME, Arakawa S, Kamidono S, Hara I. Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potential. J Urol. 2002;167:2203–8.
7. Niu Z, Li X, Hu B, Li R, Wang L, Wu L, et al. Small interfering RNA targeted to secretory clusterin blocks tumor growth, motility, and invasion in breast cancer. Acta Biochim Biophys Sin (Shanghai). 2012;44:991–8.
8. Cao C, Shinhoara ET, Li H, Niermann K, Kim KW, Sekhar KR, et al. Clusterin as a therapeutic target for radiation sensitization in a lung cancer model. Int J Radiat Oncol Biol Phys. 2005;63:1228–36.
9. Cheng CY, Cheng SH, Wu WJ, Yang TY, Huang HY, Liao FT, et al. Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells. Cancer Chemother Pharmacol. 2012;69:145–54.
10. July LV, Beraldi E, So A, Fazli L, Evans K, English JC, et al. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther. 2004;3:223–32.
11. Zhang B, Zhang K, Liu Z, Hao F, Wang M, Li X, et al. Secreted clusterin gene silencing enhances chemosensitivity of A549 cells to cisplatin through AKT and ERK1/2 pathways in vitro. Cell Physiol Biochem. 2014;33:1162–75.
12. Chou TY, Chen WC, Lee AC, Hung SM, Shih NY, Chen MY. Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway. Cell Signal. 2009;21:704–11.
13. Yan Y, Luo K, Zhang H, Chai W. RNA interference-mediated secretory clusterin gene silencing inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cells. Hepatogastroenterology. 2013;60:70–5.
14. Laskin JJ, Nicholas G, Lee C, Gittle B, Vincent M, Cormier Y, et al. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol. 2012;7:579–86.
15. Padda SK, Burt BM, Trakul N, Waleeke HA. Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy. Semin Oncol. 2014;41:40–56.
16. Bunn Jr PA, Kelly K. New combinations in the treatment of lung cancer: a time for optimism. Chest. 2000;117(4 Suppl 1):1385–435.
17. Djeu JY, Wei S. Clusterin and chemoresistance. Adv Cancer Res. 2009;105:77–92.
18. Jaattela M. Escaping cell death: survival proteins in cancer. Exp Cell Res. 1999;248:30–43.
19. Trougakos IP. Advances and challenges in basic and translational research on clusterin. Cancer Res. 2009;69:403–6.